Shop
-1.png)
eStoreRx™
Online Supplement Dispensary
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
-1.png?width=375&height=198&name=image%20(2)-1.png)
A 2026 study explored how specialized pro-resolving mediator (SPM)-enriched supplementation may influence inflammatory pathways in individuals with symptomatic knee osteoarthritis. Published in Prostaglandins, Leukotrienes and Essential Fatty Acids, the analysis examined blood plasma from participants in the GAUDI study, a randomized, multicenter, double-blind, placebo-controlled trial. Researchers evaluated changes in inflammatory biomarkers, SPMs, and related lipid mediators and examined relationships between these measures and clinical outcomes.
The researchers observed a tendency toward reductions in IL-1 and IL-18 in the SPM group compared with placebo, although these differences did not reach statistical significance. However, changes in IL-1 and IL-8 were associated with changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a validated measure of osteoarthritis-related pain, stiffness, and physical function. Changes in IL-1 and IL-6 were also associated with changes in osteoarthritis-related pain. Among individuals with a BMI ≥25 kg/m², most inflammatory biomarkers tended to decrease following SPM supplementation. The researchers also identified changes in several circulating SPMs and related lipid mediators, providing evidence of changes in specific lipid mediator pathways.
These findings build on the original GAUDI trial, which reported a statistically significant reduction in pain after 8 and 12 weeks of SPM-enriched oil supplementation compared with placebo, as well as improvements in several quality-of-life measures. The study did not find a significant change in overall WOMAC scores. Together, the findings provide further insight into the relationship between SPM supplementation, inflammatory signaling, pain, and quality of life in symptomatic knee osteoarthritis.
SPMs are a family of bioactive lipid mediators biosynthesized from polyunsaturated fatty acids (PUFAs), including the omega-3 fatty acids EPA and DHA. Unlike their PUFA precursors, SPMs are specialized downstream mediators involved in the active resolution of inflammation. Resolvins, protectins, and maresins are among the best-characterized SPM families. Rather than initiating or amplifying the inflammatory response, SPMs participate in its resolution, an active, coordinated process involving changes in immune-cell recruitment and activity, clearance of apoptotic cells and cellular debris, tissue repair, and restoration of tissue homeostasis.
A review in Nature Reviews Cardiology highlights the importance of timely resolution in limiting prolonged inflammation and supporting tissue repair. The authors also discuss the potential relevance of SPMs to vascular inflammation and atherosclerotic cardiovascular disease.
A more recent review in Pharmacology & Therapeutics further describes resolution as an endogenous process that brings inflammation toward homeostasis through specialized pro-resolving lipid mediators and other pro-resolving signals. The review highlights how dysfunctional resolution may contribute to persistent inflammation across conditions including cardiovascular, metabolic, respiratory, and inflammatory diseases.
The relationship between inflammation and resolution is particularly relevant in joint disease. A review in Current Osteoporosis Reports examined the role of SPMs following joint injury and their potential relationship to post-traumatic osteoarthritis. The authors describe how inflammation following injury is necessary for proper tissue healing, while unresolved or overactivated inflammation may contribute to chronic joint disease. SPMs have emerged as potential mediators of inflammatory resolution and tissue repair, raising interest in their role in restoring joint homeostasis following injury.
The potential relevance of SPMs also extends beyond musculoskeletal conditions. Research published in Molecules has investigated SPMs in neuroinflammation and neurological disorders, including multiple sclerosis, cerebrovascular disease, and dementia. In traumatic brain injury, research has explored the SPM lipidome as a potential biomarker of inflammatory activity and disease progression, while also examining the potential role of pro-resolving lipid mediators in recovery following injury.
Emerging research is also beginning to clarify how SPMs influence inflammatory signaling at the cellular level. A 2024 study published in PNAS found that several SPMs, including protectins, maresins, and D-series resolvins, can function as positive allosteric modulators of the prostaglandin E2 receptor EP4. Enhanced EP4 signaling promoted anti-inflammatory responses and increased macrophage phagocytosis, a process involved in the removal of apoptotic cells and cellular debris.
Collectively, these findings show that resolution is an active, essential phase of inflammation. SPMs help coordinate this transition by regulating immune-cell activity, clearing cellular debris, and restoring tissue function. Further research into SPM biosynthesis and signaling may clarify how persistent inflammation develops across tissues and disease states and inform strategies that support endogenous resolution pathways and restore tissue balance.
Submit your comment